作者: Pieter E. Postmus , Dirk Th. Sleijfer , Nanno H. Mulder
DOI: 10.1007/978-1-4613-2295-5_13
关键词:
摘要: Initially, the introduction of chemotherapy in treatment small cell lung cancer (SCLC) has considerably improved bad prognosis patients with this highly malignant tumor [1]. The change a median survival less than 3 months before into more one year as result its introduction, and observation occurrence two disease free survival, be it only number patients, led half decade ago to speculations that goal cure larger these might within reach [2]. Since time however, no further progress been made therapeutic results are still on same plateau five years ago. This disappointing reality necessitates investigation other approaches chapter high-dose (HDCT) will summarised discussed.